来源：文汇报 ■本报记者 唐闻佳 郑捷回忆，2003年，上海家化与瑞金医院皮肤科开启中国医学护肤领域最早的"医研共创"实践。这个跨 界牵手，因患者"痛点"而起。 皮肤健康不仅关乎美丽，更关乎全身健康。"研究发现，坚持皮肤屏障护理，对认知功能衰退、糖尿病 等都有一定保护作用。"近日在上海举行的全国皮肤屏障专业峰会上，瑞金医院皮肤科终身教授郑捷分 享这一前沿进展。 由瑞金医院主导的一项项研究，不仅写成论文，刷新人们对"皮肤健康"的认知，更变成了市场上的畅销 产品：被誉为"中国第一个医学护肤品"的玉泽皮肤屏障修护身体乳，多次位列平台"回购率"第一位置。 当前，我国护肤品市场正迎来前所未有的变革。《中国护肤品消费趋势报告》显示，与过去一味追求国 际大牌不同，2024年，超八成消费者表示经常购买国产护肤品。 在玉泽"叫好又叫座"的背后，"医研共创"的合作模式受到关注：瑞金医院和上海家化这两家"百年老 店"22年牵手，蹚出一条新路。 "科研基因"成国货护肤品硬核营销标签 "皮肤不仅是人体屏障，更是神经、内分泌、免疫系统'三位一体'的呈现。"郑捷介绍，近10年，三项摘 获诺贝尔奖的科研成果——Toll样受体、昼夜节律、辣椒 ...

Core Insights - The skincare market for international brands like Estée Lauder and L'Oréal is facing challenges, prompting a shift towards the medical aesthetics sector [1][4] - Estée Lauder has partnered with Jiahui Medical to establish a clinical research center focused on post-surgical skincare solutions [1][5] - The beauty industry is witnessing a trend towards "medical beauty," with brands integrating effective skincare products with medical aesthetics [4][6] Group 1: Company Strategies - Estée Lauder's brands, including La Mer and Clinique, are launching medical device products aimed at post-surgical recovery, indicating a strategic pivot towards medical aesthetics [1][5] - L'Oréal has been proactive in the medical aesthetics space, introducing products like the "Platinum Research" collagen injection and investing in high-end medical chains [6][7] - Amorepacific has also entered the market with its high-end brand "AP," focusing on post-surgical skincare products priced between 2000-3000 RMB [5][6] Group 2: Market Dynamics - The high-end skincare market is experiencing a significant decline, with Estée Lauder reporting an 8% drop in skincare sales in Q3 2024 and a further 12% in Q4 2024, leading to a total revenue loss of $300 million [4] - Competitors like Beiersdorf are also struggling, with its luxury brand La Prairie seeing a 15% sales decline in 2023 and a 6% drop in 2024 [4] - The domestic medical aesthetics market is becoming increasingly competitive, with companies like Aimeike facing growth slowdowns despite a 5.45% revenue increase in 2024 [9][10] Group 3: Future Outlook - Aimeike's acquisition of an 85% stake in Korean company REGEN for approximately 1.4 billion RMB highlights the need for companies to strengthen their technological capabilities in the face of rising competition [11] - The competition between international beauty brands and domestic medical aesthetics firms is intensifying, focusing on brand strength and clinical validation versus technological barriers and channel control [11]